Inclusion Criteria:

          -  Patients with stage III-IV HER2 negative breast cancer treated with primary or salvage
             therapy and now have:

               -  No evidence of disease (NED), or

               -  Stable bone only disease

          -  Patients who have completed standard of care and recovered with mild to no residual
             toxicity from recent therapy

          -  Patients must be at least 28 days post cytotoxic chemotherapy, and/or monoclonal
             antibody therapy (excluding bone-directed therapy), prior to enrollment

          -  Patients must be at least 28 days post systemic steroids prior to enrollment

          -  Patients on bisphosphonates, denosumab, and/or endocrine therapy are eligible

          -  Patients must have Eastern Cooperative Oncology Group (ECOG) performance status score
             of =< 1

          -  Patients must have recovered from major infections and/or surgical procedures, and in
             the opinion of the investigator, not have any significant active concurrent medical
             illnesses precluding protocol treatment

          -  Estimated life expectancy of more than 6 months

          -  White blood cells (WBC) >= 3000/mm^3 (within 30 days of first vaccination)

          -  Lymphocyte count >= 800/mm^3 (within 30 days of first vaccination)

          -  Platelet count >= 75,000/mm^3 (within 30 days of first vaccination)

          -  Hemoglobin (Hgb) >= 10 g/dl (within 30 days of first vaccination)

          -  Serum creatinine <= 1.2 mg/dl or creatinine clearance > 60 ml/min (within 30 days of
             first vaccination)

          -  Total bilirubin <= 1.5 mg/dl (within 30 days of first vaccination)

          -  Aspartate aminotransferase (AST)/serum glutamic oxaloacetic transaminase (SGOT) <= 2
             times upper limit of normal (ULN) (within 30 days of first vaccination)

          -  Blood glucose < 1.5 ULN (within 30 days of first vaccination)

          -  All patients who are having sex that can lead to pregnancy must agree to contraception
             for the duration of study

        Exclusion Criteria:

          -  Patients with any of the following cardiac conditions:

               -  Symptomatic restrictive cardiomyopathy

               -  Unstable angina within 4 months prior to enrollment

               -  New York Heart Association functional class III-IV heart failure on active
                  treatment

               -  Symptomatic pericardial effusion

          -  Patients at risk for gastrointestinal bleeding (example: peptic ulcer disease,
             prolonged daily non-steroidal anti-inflammatory use)

          -  Patients with any seizure disorder

          -  Patients with any contraindication to receiving rhuGM-CSF based products

          -  Patients with any clinically significant autoimmune disease uncontrolled with
             treatment

          -  Patients who are simultaneously enrolled in any other treatment study

          -  Patients who are pregnant or breastfeeding